Navigation Links
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
Date:2/23/2009

f 1934, as amended, shares tendered during the subsequent offer period may not be withdrawn.

Endo and BTB reserve the right to extend the subsequent offering period in accordance with applicable law. After expiration of the subsequent offering period, BTB will acquire all of the remaining outstanding shares of Indevus common stock by means of a merger under Delaware law. As a result of the purchase of shares in the tender offer, BTB has sufficient voting power to approve the merger without the affirmative vote of any other Indevus stockholder. Following the merger, Indevus will become a wholly-owned subsidiary of Endo, and each share of Indevus' outstanding common stock will be cancelled and converted into the right to receive the same consideration, without interest, received by holders who tendered in the tender offer. Thereafter, Indevus common stock will cease to be traded on the NASDAQ Stock Market.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neuro
'/>"/>

SOURCE Endo Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... be used for detailed studies of what happens on ... pharmaceuticals research, among other applications. A group of researchers ... artificial cell membranes form across a large number of ... between the interior of a cell and its surroundings ... a surface layer that holds the cell together and ...
(Date:9/2/2014)... 2014 Persistence Market Research ( ... Pharmaceutical, Biopharma and Life Sciences: North America ... membrane technology market for pharmaceutical, biopharma and life sciences is ... expected to grow at a CAGR of 9.1% from ... USD 10,886.0 million in 2019. Browse the ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... release is available in German . ... with microelectronic components gradually being replaced by nanoelectronic ... the present stage the most commonly used material ... further miniaturization and technological progress. New electronic materials ...
... Rosei of the INRS Energy Materials Telecommunications Center has ... Friedrich Wilhelm Bessel Research Award given by the Alexander ... awards annually to young, high level researchers around the ... caliber and scope of his research in the field ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported financial and operational results for the ... For the third quarter of 2010, PharmAthene ... in the same period of 2009.  For the nine ...
Cached Biology Technology:Step by step toward tomorrow's nanomaterial 2INRS professor Federico Rosei receives a 2010 Friedrich Wilhelm Bessel Research Award 2PharmAthene Reports Third Quarter 2010 Financial and Operational Results 2PharmAthene Reports Third Quarter 2010 Financial and Operational Results 3PharmAthene Reports Third Quarter 2010 Financial and Operational Results 4PharmAthene Reports Third Quarter 2010 Financial and Operational Results 5PharmAthene Reports Third Quarter 2010 Financial and Operational Results 6PharmAthene Reports Third Quarter 2010 Financial and Operational Results 7
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... 2, 2014 Best-selling author Sam Kean stops by ... Megalodon, the 50-foot super shark that, despite what "Shark ... Learn all about it at http://youtu.be/KhFygIoW_MA . , ... of Madness, Love and the History of the World ... the Reactions treatment in a 10-episode video series produced ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... The apparently random self-assembly of molecular threads into the ... frantic than previously thought, Michigan State University scientists say. ... the nature of some diseases. How proteins spontaneously ... wide variety of functional or malfunctioning three-dimensional ...
... A phylogenetic analysis can take a long time to ... efficiently and effectively. The National Institute for Mathematical and ... focusing on high performance computing (HPC) for phylogenetics. ... to use TeraGrid, the CIPRES Portal, the iPlant Discovery ...
... The American Physical Society (APS) announces a new public ... public libraries in the United States full use of ... back to the first issue in 1893, a collection ... provide this access at no cost to participating public ...
Cached Biology News:Scientists post lower speed limit for cell-signaling protein assembly 2
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: